Abcam has been granted a patent for a method of screening antibodies. The method involves obtaining nucleotide sequences of the variable domains of a first antibody, screening a large number of variable domain sequences to identify related sequences, and testing these sequences to identify a second antibody that binds to the same antigen. The method aims to streamline the process of antibody discovery and development. GlobalData’s report on Abcam gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Abcam, CRISPR nucleases was a key innovation area identified from patents. Abcam's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Method of screening antibodies based on lineage and antigen binding
A recently granted patent (Publication Number: US11661598B2) describes a method for screening and producing antibodies. The method involves obtaining the amino acid or nucleotide sequences of the variable domains of a first antibody from an animal. At least 100,000 variable domain sequences representing a portion of the animal's antibody repertoire are then obtained. These sequences are computationally screened to identify related sequences that are lineage to the variable domains of the first antibody. In vitro testing is conducted on the identified sequences to identify a second antibody that binds to the same antigen as the first antibody.
The testing step in the method may involve testing at least 10% of all possible combinations of heavy and light chain variable domain sequences for binding to the antigen. The sequences tested can be randomly selected from the obtained variable domain sequences. The method also includes steps for producing the identified antibodies. This involves introducing the nucleic acid encoding the identified heavy and light chain variable domain sequences into a host cell in vitro. The host cell is then incubated to allow for the expression of the antibody. The expressed antibody is purified to produce the second antibody that binds to the same antigen as the first antibody.
The method described in the patent can be used with various animals, including rabbits, humans, mice, and chickens. The animals may have been immunized with the antigen multiple times in the presence of an adjuvant. Additionally, the method can be used with animals that have autoimmune diseases, resistance to diseases, or have recovered from diseases. The specificity and affinity of the second antibody to the antigen can be determined through testing.
Overall, this patent provides a method for screening and producing antibodies by computationally analyzing variable domain sequences and conducting in vitro testing. The method has potential applications in various fields, including therapeutic antibody development and diagnostics.
To know more about GlobalData’s detailed insights on Abcam, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
